Freeman Technology and GEA Pharma Systems Collaborate to Advance Continuous Manufacturing for Pharma
Freeman Technology, a global provider of powder testing instruments, and GEA Pharma Systems, a company that specialises in the design and development of processing solutions for the pharmaceutical industry, are collaborating to advance the application of continuous wet granulation and drying technology in the pharmaceutical industry.
The work involves Freeman Technology’s FT4 Powder Rheometer and GEA Pharma Systems’ ConsiGma 1 continuous granulation unit. Data from the FT4 are being used to quantify the influence of the operating conditions of the ConsiGma1 on the bulk characteristics of the granules being manufactured. These data are then correlated to attributes of the tablets, providing the link between granule and tablet properties. An application note detailing the study can be can be accessed by clicking here.
Pharmaceutical manufacturers frequently utilise wet granulation as a precursor to tableting, with the current trend moving from traditional batch manufacturing towards integrated continuous processing. Consequently there is a requirement for continuous wet granulation technology. The ConsiGma 1 is a laboratory-scale version of GEA Pharma Systems’ ConsiGma concept, which incorporates a patented continuous high shear granulator and small batch dryer, and has been developed specifically to meet this continuous wet granulation need.
The FT4 Powder Rheometer enables the measurement of bulk, shear and dynamic powder properties that can be correlated directly with process performance and product quality. It is therefore a powerful tool for scoping the design space for powder processes, as advocated by QbD. Identification of the operating envelope that results in product with the defined critical quality attributes (CQAs) is a central strategy for ensuring consistent clinical efficacy. This operating envelope is the design space for the process.
In this study, dynamic properties were measured to quantify the impact of granulation process variables on the quality of granules produced. Paracetamol (APAP) and dicalcium phosphate (DCP) blends were used in the work. These dynamic properties were also successfully correlated with the CQAs of finished tablets, such as hardness.
The study rigorously investigated the impact of changes in water addition level, granulator screw speed, and powder feed rate. The results show how it is possible to produce granules of closely defined quality using a series of different operating conditions, and demonstrate how the design space for the ConsiGma can be mapped efficiently for a given tableting blend. Dynamic powder measurements provide the information needed to effectively specify optimal operating conditions. Within a commercial manufacturing environment they would also provide the information needed for operational decision making, within the design space.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance